

US009561177B2

## (12) United States Patent

Keegan et al.

## (10) Patent No.: US 9,561,177 B2

(45) **Date of Patent:** \*Feb. 7, 2017

# (54) NASAL DRUG PRODUCTS AND METHODS OF THEIR USE

(71) Applicants: Adapt Pharma Limited, Dublin (IE);
Opiant Pharmaceuticals, Santa
Monica, CA (US)

(72) Inventors: Fintan Keegan, Dublin (IE); Robert Gerard Bell, Clearwater, FL (US); Roger Crystal, Santa Monica, CA (US); Michael Brenner Weiss, New

York, NY (US)

(73) Assignees: **ADAPT PHARMA LIMITED**, Dublin (IE); **OPIANT** 

PHARMACEUTICALS, Santa Monica, CA (US)

Monica, CA (US

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 15/183,441

(22) Filed: Jun. 15, 2016

#### (65) Prior Publication Data

US 2016/0303041 A1 Oct. 20, 2016

#### Related U.S. Application Data

- (63) Continuation-in-part of application No. 14/950,707, filed on Nov. 24, 2015, now Pat. No. 9,468,747, which is a continuation of application No. 14/942,344, filed on Nov. 16, 2015, now Pat. No. 9,480,644, which is a continuation-in-part of application No. 14/659,472, filed on Mar. 16, 2015, now Pat. No. 9,211,253.
- (60) Provisional application No. 61/953,379, filed on Mar. 14, 2014, provisional application No. 62/274,536, filed on Jan. 4, 2016, provisional application No. 62/219,955, filed on Sep. 17, 2015.

(2013.01); A61K 31/485 (2013.01); A61K

| (51) | Int. Cl.    |                                  |
|------|-------------|----------------------------------|
| (51) |             |                                  |
|      | A61M 31/00  | (2006.01)                        |
|      | A61M 5/00   | (2006.01)                        |
|      | A61F 13/00  | (2006.01)                        |
|      | A61K 31/56  | (2006.01)                        |
|      | A61K 9/00   | (2006.01)                        |
|      | A61K 9/08   | (2006.01)                        |
|      | A61K 31/485 | (2006.01)                        |
|      | A61K 47/02  | (2006.01)                        |
|      | A61K 47/18  | (2006.01)                        |
|      | A61M 15/08  | (2006.01)                        |
|      | A61M 11/00  | (2006.01)                        |
| (52) | U.S. Cl.    |                                  |
| ` ′  | CPC         | A61K 9/0043 (2013.01); A61K 9/08 |

(2014.02); A61M 11/006 (2014.02); A61M 11/007 (2014.02); A61M 15/08 (2013.01); A61M 31/00 (2013.01)

#### (58) Field of Classification Search

None

See application file for complete search history.

#### (56) References Cited

#### U.S. PATENT DOCUMENTS

| 4,181,726    | Δ             | 1/1980  | Bernstein 424/260         |
|--------------|---------------|---------|---------------------------|
| , ,          |               |         |                           |
| 4,464,378    |               | 8/1984  | Hussain 424/260           |
| 5,866,154    | Α             | 2/1999  | Bahal et al 424/423       |
| 9,192,570    | B2            | 11/2015 | Wyse et al.               |
| 9,211,253    | B2            | 12/2015 | Crystal et al.            |
| 2003/0077300 | A1            | 4/2003  | Wermeling 424/400         |
| 2006/0120967 | $\mathbf{A}1$ | 6/2006  | Namburi et al 424/45      |
| 2009/0017102 | A1            | 1/2009  | Stinchcomb et al 424/449  |
| 2010/0113495 | A1            | 5/2010  | Wermeling et al 514/282   |
| 2010/0168147 | A1            | 7/2010  | Chapleo et al 514/282     |
| 2010/0331354 | A1            | 12/2010 | Wermeling 514/282         |
| 2011/0046172 | A1            | 2/2011  | Chapleo et al 514/282     |
| 2012/0270895 | A1            | 10/2012 | Wermeling 514/282         |
| 2013/0023825 | A1            | 1/2013  | Edwards et al 604/143     |
| 2015/0174061 | A1            | 6/2015  | Wyse et al A61K 9/0043    |
| 2015/0258019 | $\mathbf{A}1$ | 9/2015  | Crystal et al A61K 9/0043 |
| 2016/0008277 | $\mathbf{A}1$ | 1/2016  | Crystal et al.            |
|              |               |         |                           |

#### FOREIGN PATENT DOCUMENTS

| CN | 1575795        | 2/2005  | A61K 31/485 |
|----|----------------|---------|-------------|
| EP | 1681057        | 7/2006  | A61K 31/485 |
| WO | WO 82/03768    | 11/1982 | A61K 31/40  |
| WO | WO 98/30211    | 7/1998  | A61K 9/72   |
| WO | WO 00/62757    | 10/2000 | A61K 9/00   |
| WO | WO 00/74652    | 12/2000 | A61K 9/12   |
| WO | WO 01/58447    | 8/2001  | A61K 31/44  |
| WO | WO 01/82931    | 11/2001 | A61M 31/52  |
| WO | WO 02/11778    | 2/2002  | A61L 9/04   |
| WO | WO 03/084520   | 10/2003 | A61M 31/00  |
| WO | WO 2004/054511 | 7/2004  |             |
| WO | WO 2005/020906 | 3/2005  |             |
|    |                |         |             |

(Continued)

#### OTHER PUBLICATIONS

Djupesland; Drug Deliv. and Transl. Res. (2013) 3:42-62.\* (Continued)

Primary Examiner — Jeffrey T Palenik

(74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, P.L.C.

#### (57) ABSTRACT

Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.



#### (56)References Cited

#### FOREIGN PATENT DOCUMENTS

| WO | WO 2006/089973 | 8/2006  | A61K 9/28   |
|----|----------------|---------|-------------|
| WO | WO 2007/083073 | 7/2007  | A61M 15/08  |
| WO | 2009/040595    | 4/2009  | A61K 9/00   |
| WO | WO 2012/026963 | 3/2012  | A61M 15/00  |
| WO | WO 2012/156317 | 11/2012 | A61K 9/00   |
| WO | WO 2013/128447 | 9/2013  | A61M 15/08  |
| WO | 2014/016653    | 1/2014  | A61K 31/485 |
| WO | WO 2015/095644 | 6/2015  | A61K 47/12  |
| WO | WO 2015/136373 | 9/2015  | A61K 31/485 |
| WO | 2016/007729    | 1/2016  | A61K 9/00   |

#### OTHER PUBLICATIONS

Kundoor et al.; Pharm. Res. (2011) 28:189501904.\*

Makidon et al.; Journal of Aerosol Medicine and Pulmonary Drug Delivery; vol. 23, No. 2 (2010); pp. 77-89.\*

U.S. Patent Documents-None.\*

International Search Report (ISR), dated Sep. 2, 2015 in International Application No. PCT/IB2015/000941, 4 pgs.

Krieter, P., et al. (2016) "Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose." The Journal of Clinical Pharmacology, pp. 1-11.

Aptar UnitDose and BiDose product information sheet, available at www.aptar.com/docs/pharmaprescription/uds-bds-datasheet.pdf, publication date unknown, last accessed Mar. 26, 2015.

Ashton, H., et al., "Best evidence topic report. Intranasal naloxone in suspected opioid overdose.", Emerg. Med. J., 23(3):221-23 (published Mar. 2006).

Bailey, A.M., et al., "Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings." Ann. Pharmacother, 48(5):601-06 (published May 2014).

Barton, E.D. et al., "Intranasal administration of naloxone by paramedics." Prehosp. Emerg. Care, 6(1):54-58 (published Jan. 2002).

Barton, E.D. et al., "Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting." J. Emerg. Med., 29(3):265-271 (published Oct. 2005).

Beletsky, L. et al., "Physicians\_Knowledge of and Willingness to Prescribe Naloxone to Reverse Accidental Opiate Overdose: Challenges and Opportunities." Journal of Urban Health: Bulletin of the New York Academy of Medicine, 84(1):126-136 (published 2006). Doe-Simkins, M. et al., "Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose." Am. J. Public Health, 99(5):788-791 (published May 2009)

Dowling, J. et al., "Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers." Ther Drug Monit, 30(4):490-496 (published Aug. 2008).

Heard, C. et al., "Intranasal flumazenil and naloxone to reverse over-sedation in a child undergoing dental restorations." Paediatr. Anaesth., 19(8):795-99 (published Aug. 2009).

Kelly, A.M. et al., "Intranasal naloxone for life threatening opioid

toxicity." Emerg. Med. J., 19(4):375 (published Jul. 2002). Kelly, A.M. et al., "Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose." Med. J. Aust. 182(1):24-27 (published Jan. 3, 2005).

Kerr, D. et al., "Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose." Addiction 104(12):2067-2074 (Epub Nov. 9, 2009).

Loimer, N. et al., "Nasal administration of naloxone for detection of opiate dependence." J. Psychiatr. Res., 26(1):39-43 (published Jan. 1992)

Loimer, N. et al., "Nasal administration of naloxone is as effective as the intravenous route in opiate addicts." Int. J. Addict., 29(6):819-27 (published Apr. 1994).

Merlin, M. A. et al., "Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses." Am. J. Emerg. Med., 28(3):296-303 (Epub Jan. 28, 2010).

Robertson, T. M., "Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose." Prehosp. Emerg. Care, 13(4):512-15 (Published Oct. 2009).

Walley, A.Y., et al., "Opioid overdose prevention with intranasal naloxone among people who take methadone." J. Subst. Abuse Treat., 44(2):241-47 (Epub Sep. 12, 2012).

Walley, A.Y., et al, "Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis." BMJ 346:f174, (Published Jan. 31, 2013).

Weber, J. M. et al., "Can nebulized naloxone be used safely and effectively by emergency medical services for suspected opioid overdose=" Prehosp. Emerg. Care, 16(2):289-92 (Epub Dec. 22,

Wermeling, D.P. et al., "Opioid harm reduction strategies: focus on expanded access to intranasal naloxone." Pharmacotherapy 30(7):627-31 (published 2010).

Wermeling, D.P. et al., "A response to the opioid overdose epidemic: naloxone nasal spray." Drug Delivery Transl. Res., 3(1):63-74 (published Feb. 1, 2013).

International Search Report (ISR) and Written Opinion (WO), dated Aug. 25, 2014 in International Application No. PCT/EP2014/ 064032 (WO 2015/000941) 11 pgs.

Notice of Allowance and Fees Due, dated Oct. 9, 2015 in U.S. Appl. No. 14/659,472, 9 pgs.

Corrected Notice of Allowance and Fees Due, dated Nov. 9, 2015 in U.S. Appl. No. 14/659,472, 9 pgs. TEVA Pharmaceuticals USA, Inc., "Notice of ANDA No. 209522

naloxone hydrochloride nasal spray, 4 mg/spray, with paragraph IV certification concerning U.S. Pat. No. 9,211,253", dated Sep. 13,

\* cited by examiner






FIG. 1




FIG. 2




FIG. 3A




FIG. 3B

# DOCKET A L A R M

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

